Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Has Consensus Target Price of $21.00 According to Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have been assigned an average rating of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $21.00.

A number of brokerages have issued reports on AMRX. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. The Goldman Sachs Group restated a “buy” rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Zacks Research downgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. Barclays lifted their price target on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, September 17th. Finally, Leerink Partners began coverage on shares of Amneal Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $23.00 target price on the stock.

Amneal Pharmaceuticals Trading Up 2.5%

Shares of AMRX stock opened at $19.84 on Wednesday. The company has a market capitalization of $6.34 billion, a PE ratio of 40.49, a price-to-earnings-growth ratio of 2.27 and a beta of 1.22. Amneal Pharmaceuticals has a 52-week low of $9.99 and a 52-week high of $21.17. The business’s fifty day moving average is $18.63 and its 200 day moving average is $16.31. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The company had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, equities research analysts anticipate that Amneal Pharmaceuticals will post 0.95 EPS for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other news, Director John Kiely sold 50,000 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the sale, the director directly owned 210,252 shares in the company, valued at $3,708,845.28. This represents a 19.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Jason Daly sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the sale, the executive vice president owned 35,171 shares in the company, valued at approximately $611,975.40. The trade was a 85.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 413,016 shares of company stock worth $7,216,567 in the last quarter. Company insiders own 17.30% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its position in shares of Amneal Pharmaceuticals by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after buying an additional 81,546 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Amneal Pharmaceuticals by 72.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after purchasing an additional 1,069,400 shares during the last quarter. Congress Asset Management Co. raised its holdings in Amneal Pharmaceuticals by 94.7% during the 3rd quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock valued at $30,701,000 after buying an additional 741,577 shares during the period. Bank of New York Mellon Corp bought a new stake in Amneal Pharmaceuticals in the second quarter worth $17,573,000. Finally, Principal Financial Group Inc. lifted its position in Amneal Pharmaceuticals by 527.9% in the first quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock worth $12,089,000 after buying an additional 817,652 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.